La Jolla Pharmaceutical

Latest Headlines

Latest Headlines

La Jolla dumps its NASH drug and shifts its focus to rare disease

La Jolla Pharmaceutical is pulling the plug on a pair of projects--including one for the common liver disease NASH--after the FDA set out a difficult regulatory road ahead.

La Jolla leaps on NASH fervor thanks to some preclinical success

Successfully treating a mouse is not usually enough to get investors excited, but the promise of an effective drug for nonalcoholic steatohepatitis sent La Jolla Pharmaceuticals' shares up as much as 20% on Tuesday despite very early data.

La Jolla soars as kidney drug impresses in Phase II, but dosing questions linger

La Jolla Pharmaceutical's chronic kidney disease drug hit its primary endpoint of improving organ function in a Phase II trial, the company said, and while the results sent the biotech's shares skyward by 75%, a quirk in dosing gave some analysts pause.

La Jolla Pharma to be delisted after merger flop

La Jolla Pharmaceutical is running out of options. Few shareholders bothered to even respond to its latest effort at a merger, and now the one-time high flyer says that its shares will be delisted

La Jolla pleads for shareholders to vote on merger

La Jolla Pharmaceutical is trying hard to get its investors' attention. In order to complete a proposed merger with Adamis Pharmaceuticals, it has to get an endorsement from the holders of at least

La Jolla Pharma throws in the towel

In April, La Jolla Pharmaceutical warned that if it wasn't able to raise funds, a merger, license agreement or other collaboration, it would have to liquidate. And with no "knight in shining armor"

After trial failure, doubts about La Jolla's future

La Jolla Pharmaceuticals is on the edge of the abyss after announcing in February that it's lupus drug Riquent was a bust. Not long after that the company cut an unspecified number of jobs and said

BioMarin loses $15M bet on Riquent

Just a few months after paying La Jolla Pharmaceutical $7.5 million while buying another $7.5 million in its stock, BioMarin Pharmaceutical has returned its rights to Riquent, which recently failed a

La Jolla 'evaluates options' after trial failure

Following last week's announcement that it's lead drug failed a Phase III trial, La Jolla Pharmaceutical announced that it is taking steps to preserve its cash, including a "substantial reduction"

La Jolla shelves Riquent, shares plummet

Investors swiftly wiped out 82 percent of La Jolla Pharmaceutical's stock value after learning that its lupus drug--Riquent--was being shelved after an interim analysis revealed negative late-stage